Article
Expression of the non-coding RNA nc886 facilitates the development of tyrosine kinase inhibitor resistance in EGFR-mutated non-small-cell lung cancer cells.
Biochemical and biophysical research communications - 30 Oct 2024
Bui Vivian N V, Daugaard Tina F, Sorensen Boe S, Nielsen Anders L
Abstract excerpt
Treatment of non-small-cell lung cancer (NSCLC) patients possessing EGFR-activating mutations with tyrosine kinase inhibitors (TKIs) can confer an initial promising response. However, TKI resistance inevitably arises. Numerous TKI resistance mechanisms are identified including EGFR secondary mutations, bypass receptor tyrosine kinase (RTK) signaling, and cellular transition e.g. epithelial-mesenchymal transition...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
